Published in Sarcoma on February 20, 2012
Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis. Front Oncol (2016) 0.85
Inhibition of KIT-glycosylation by 2-deoxyglucose abrogates KIT-signaling and combination with ABT-263 synergistically induces apoptosis in gastrointestinal stromal tumor. PLoS One (2015) 0.81
Prognosis value of Hypoxia-inducible factor-1α expression in patients with bone and soft tissue sarcoma: a meta-analysis. Springerplus (2016) 0.76
Intratumoral oxygen gradients mediate sarcoma cell invasion. Proc Natl Acad Sci U S A (2016) 0.76
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
On the origin of cancer cells. Science (1956) 49.55
A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol (1992) 11.03
Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res (1999) 10.65
Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev (1997) 8.51
Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature (2006) 8.16
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene (2009) 8.01
Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res (1996) 6.62
A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc Natl Acad Sci U S A (1997) 6.11
Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res (1996) 4.98
The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology (2006) 4.14
Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet (2001) 3.99
Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol (1997) 3.60
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J Clin Oncol (2007) 3.50
Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today (2007) 3.36
Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer (2001) 3.10
Hypoxia and cancer. J Mol Med (Berl) (2007) 2.89
Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol (2008) 2.85
Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr (1998) 2.82
Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. Cancer Res (2009) 2.62
Prolonged hypoxia differentially regulates hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression in lung epithelial cells: implication of natural antisense HIF-1alpha. J Biol Chem (2004) 2.42
Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer (2003) 2.37
Overexpression of Glut1 and Glut3 in stage I nonsmall cell lung carcinoma is associated with poor survival. Cancer (1997) 1.97
Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. Cancer Res (1996) 1.84
HIF-1α and HIF-2α correlate with migration and invasion in gastric cancer. Cancer Biol Ther (2010) 1.83
GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer (1998) 1.68
Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res (2004) 1.62
Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? Biochim Biophys Acta (2009) 1.55
Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. Cancer Res (2006) 1.50
Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res (2007) 1.41
Targeting tumor-associated carbonic anhydrase IX in cancer therapy. Trends Pharmacol Sci (2006) 1.27
GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer (2001) 1.27
High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer (2010) 1.26
Hypoxia upregulates hypoxia inducible factor (HIF)-3alpha expression in lung epithelial cells: characterization and comparison with HIF-1alpha. Cell Res (2006) 1.22
Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix. Cytometry B Clin Cytom (2006) 1.20
Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography. Eur J Nucl Med Mol Imaging (2006) 1.20
Endogenous markers of tumor hypoxia predictors of clinical radiation resistance? Strahlenther Onkol (2003) 1.14
The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys (1996) 1.11
Hypoxia rapidly activates HIF-3alpha mRNA expression. FASEB J (2003) 1.09
Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors. Cancer (2010) 1.08
Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities. Cancer Res (2000) 1.06
Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas. Oncol Rep (2010) 1.01
Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer. BMC Cancer (2011) 0.97
Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis. PLoS One (2010) 0.94
GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms. Hum Pathol (2008) 0.93
In vivo and in vitro effects of a HIF-1alpha inhibitor, RX-0047. J Cell Biochem (2008) 0.93
Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis. Mod Pathol (2009) 0.92
Expression of hypoxia-inducible factor (HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas. Virchows Arch (2006) 0.91
Endogenous hypoxia markers: case not proven! Adv Exp Med Biol (2008) 0.90
Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours. Histopathology (2010) 0.89
Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. J Oral Pathol Med (2009) 0.88
Identifying hypoxia in human tumors: A correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode. Acta Oncol (2010) 0.88
Prognostic implications of glucose transporter protein-1 (glut-1) overexpression in bone and soft-tissue sarcomas. Jpn J Clin Oncol (2007) 0.86
Serum carbonic anhydrase IX during first-line therapy of ovarian cancer. Gynecol Oncol (2010) 0.84
Positron Emission Tomography Imaging of Hypoxia. PET Clin (2009) 0.82
Glucose transporter-1 expression in squamous cell carcinoma of the tongue. Cancer Res Treat (2007) 0.78
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol (2002) 2.65
Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res (2008) 2.37
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.93
[What does the Tidsskriftet's editorial committee do?]. Tidsskr Nor Laegeforen (2009) 1.93
Paternity following treatment for testicular cancer. J Natl Cancer Inst (2005) 1.87
Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group. J Clin Oncol (2011) 1.73
Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol (2003) 1.71
Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol (2009) 1.65
The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol (2011) 1.49
Paternity and testicular function among testicular cancer survivors treated with two to four cycles of cisplatin-based chemotherapy. Eur Urol (2010) 1.43
The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol (2011) 1.43
Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer (2010) 1.42
Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. Clin Cancer Res (2007) 1.41
[Does use of alternative medicine aggravate the survival prognosis in cancer?]. Tidsskr Nor Laegeforen (2003) 1.40
Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol (2010) 1.36
The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology (2009) 1.28
Prognostic impact of MiR-155 in non-small cell lung cancer evaluated by in situ hybridization. J Transl Med (2011) 1.27
Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol (2012) 1.26
Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer: coexpression with vascular endothelial growth factor-A predicts poor survival. Cancer (2011) 1.24
gamma-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene (2002) 1.19
Prognostic impact of platelet-derived growth factors in non-small cell lung cancer tumor and stromal cells. J Thorac Oncol (2008) 1.16
Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer (2010) 1.13
MicroRNA signatures in tumor tissue related to angiogenesis in non-small cell lung cancer. PLoS One (2012) 1.07
Prognostic impact of lymphocytes in soft tissue sarcomas. PLoS One (2011) 1.06
Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J Thorac Oncol (2011) 1.05
Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J Natl Cancer Inst (2009) 1.04
Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival. J Thorac Oncol (2009) 1.03
Diverse prognostic roles of Akt isoforms, PTEN and PI3K in tumor epithelial cells and stromal compartment in non-small cell lung cancer. Anticancer Res (2009) 1.01
Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group. J Clin Oncol (2011) 0.99
The prognostic impact of TGF-β1, fascin, NF-κB and PKC-ζ expression in soft tissue sarcomas. PLoS One (2011) 0.99
Prognostic scores in patients with brain metastases from non-small cell lung cancer. J Thorac Oncol (2009) 0.99
Ewing sarcoma-peripheral neuroectodermal tumor of the kidney with a FUS-ERG fusion transcript. Cancer Genet Cytogenet (2009) 0.98
Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer (2010) 0.97
Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiat Oncol (2012) 0.96
Prognostic impacts of angiopoietins in NSCLC tumor cells and stroma: VEGF-A impact is strongly associated with Ang-2. PLoS One (2011) 0.95
Profiling of VEGFs and VEGFRs as prognostic factors in soft tissue sarcoma: VEGFR-3 is an independent predictor of poor prognosis. PLoS One (2010) 0.94
Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol (2009) 0.93
Disease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time. BMC Urol (2014) 0.92
Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival. PLoS One (2011) 0.91
The association between self-reported physical activity and prevalence of depression and anxiety disorder in long-term survivors of testicular cancer and men in a general population sample. Support Care Cancer (2005) 0.91
Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas. PLoS One (2012) 0.90
Overexpression of matrix metalloproteinase-7 and -9 in NSCLC tumor and stromal cells: correlation with a favorable clinical outcome. Lung Cancer (2011) 0.90
Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer. J Thorac Dis (2012) 0.89
Analysis of c-kit expression in small cell lung cancer: prevalence and prognostic implications. Lung Cancer (2006) 0.89
Chemotherapy and quality of life in NSCLC PS 2 patients. Acta Oncol (2009) 0.89
Stage and tissue-specific prognostic impact of miR-182 in NSCLC. BMC Cancer (2014) 0.88